Despite remarkable progress in our understanding of tumor immunity and genomic analysis in recent decades, which has led to the development of novel immune checkpoint inhibitor and BRAF/MEK inhibitor therapies for melanoma, the treatment of patients with advanced melanoma remains challenging. Here, MAP2K7 is linked to melanoma.